Liquidia (LQDA) closed at $55.21 on November 11, 2026, up 7.4% from the previous close, on volume of 3,531,823 shares (30-day average 5,715,039).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 14, 2026 | Call with Delta Hedge | 15-Jan-27 50 C +200,600 Stock | 8,099 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
Liquidia extends gains as Raymond James upgrades on Yutrepia launch
Seeking Alpha News (Wed, 11-Nov 10:46 AM ET)
TipRanks (Wed, 11-Nov 5:50 AM ET)
BTIG Reaffirms Their Buy Rating on Liquidia Technologies (LQDA)
TipRanks (Wed, 11-Nov 5:38 AM ET)
Wells Fargo Sticks to Its Hold Rating for Liquidia Technologies (LQDA)
TipRanks (Wed, 11-Nov 5:38 AM ET)
Liquidia Faces Financing Strain as YUTREPIA Restrictions Threaten Revenue and Strategic Flexibility
TipRanks (Wed, 11-Nov 1:01 AM ET)
Liquidia Technologies Earnings Call Signals Strong Growth
TipRanks (Tue, 10-Nov 7:10 PM ET)
Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
Globe Newswire (Tue, 10-Nov 8:00 AM ET)
Liquidia Reports Strong Third-Quarter YUTREPIA Sales Growth
TipRanks (Tue, 10-Nov 7:36 AM ET)
Liquidia GAAP EPS of -$2.64 misses by $3.60, revenue of $225.3M beats by $11.15M
Seeking Alpha News (Tue, 10-Nov 6:36 AM ET)
Liquidia Corporation Reports Third Quarter 2026 Financial Results
Globe Newswire (Tue, 10-Nov 6:30 AM ET)
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Liquidia trades on the NASDAQ stock market under the symbol LQDA.
As of November 12, 2026, LQDA stock price climbed to $58.16 with 1,032,836 million shares trading.
LQDA has a beta of 0.51, meaning it tends to be less sensitive to market movements. LQDA has a correlation of 0.00 to the broad based SPY ETF.
LQDA has a market cap of $5.17 billion. This is considered a Mid Cap stock.
Last quarter Liquidia reported $225 million in Revenue and $1.71 earnings per share. This beat revenue expectation by $16 million and exceeded earnings estimates by $.78.
In the last 3 years, LQDA traded as high as $93.61 and as low as $6.10.
The top ETF exchange traded funds that LQDA belongs to (by Net Assets): IJR, IWM, VTI, XSMO, SPSM.
LQDA has outperformed the market in the last year with a price return of +109.4% while the SPY ETF gained +12.5%. However, in the short term, LQDA had mixed performance relative to the market. It has underperformed in the last 3 months, returning -33.9% vs -1.0% return in SPY. But in the last 2 weeks, LQDA shares have fared better than the market returning +27.2% compared to SPY -1.5%.
LQDA support price is $52.00 and resistance is $58.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LQDA shares will trade within this expected range on the day.
